The purpose of this study is to evaluate the safety and effectiveness of the investigational drugs pimasertib and SAR245409 in women with previously treated inoperable low-grade ovarian or primary peritoneal cancer. Patients will be randomly assigned to receive pimasertib with SAR245409 or pimasertib with a placebo. Researchers will also search for genetic markers that may predict how a patient will respond to treatment.
Pimasertib works by inhibiting MEK, a protein which fuels the growth of some cancers. SAR245409 works by inhibiting PI3 kinase and mTOR, which are also proteins involved in cancer growth. Doctors think that both drugs given together may be more effective than either alone. Both pimasertib and SAR245409 are taken orally (by mouth).